I1NC34 Stock Overview
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$135.90 |
| 52 Week High | US$164.30 |
| 52 Week Low | US$135.90 |
| Beta | 0.67 |
| 1 Month Change | -6.21% |
| 3 Month Change | -11.00% |
| 1 Year Change | -20.69% |
| 3 Year Change | -42.17% |
| 5 Year Change | n/a |
| Change since IPO | -15.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| I1NC34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 0.4% |
| 1Y | -20.7% | -2.8% | 14.6% |
Return vs Industry: I1NC34 underperformed the BR Biotechs industry which returned -4% over the past year.
Return vs Market: I1NC34 underperformed the BR Market which returned 16.7% over the past year.
Price Volatility
| I1NC34 volatility | |
|---|---|
| I1NC34 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.9% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: I1NC34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine I1NC34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,524 | Herve Hoppenot | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors.
Incyte Corporation Fundamentals Summary
| I1NC34 fundamental statistics | |
|---|---|
| Market cap | R$60.78b |
| Earnings (TTM) | R$3.81b |
| Revenue (TTM) | R$19.27b |
16.0x
P/E Ratio3.2x
P/S RatioIs I1NC34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I1NC34 income statement (TTM) | |
|---|---|
| Revenue | US$3.77b |
| Cost of Revenue | US$1.91b |
| Gross Profit | US$1.86b |
| Other Expenses | US$1.12b |
| Earnings | US$745.44m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.32 |
| Gross Margin | 49.42% |
| Net Profit Margin | 19.78% |
| Debt/Equity Ratio | 0% |
How did I1NC34 perform over the long term?
See historical performance and comparison